LENSAR, Inc. (NASDAQ:LNSR) Short Interest Down 22.6% in October

LENSAR, Inc. (NASDAQ:LNSR) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 49,800 shares, a decrease of 22.6% from the October 15th total of 64,300 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average daily trading volume, of 31,200 shares, the days-to-cover ratio is presently 1.6 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC purchased a new stake in shares of LENSAR in the second quarter worth $93,000. Geode Capital Management LLC boosted its stake in LENSAR by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after purchasing an additional 3,423 shares in the last quarter. DCF Advisers LLC boosted its stake in LENSAR by 1.4% in the 2nd quarter. DCF Advisers LLC now owns 241,484 shares of the company’s stock worth $1,087,000 after purchasing an additional 3,250 shares in the last quarter. Finally, Brandes Investment Partners LP grew its position in LENSAR by 12.8% during the 2nd quarter. Brandes Investment Partners LP now owns 373,198 shares of the company’s stock valued at $1,644,000 after purchasing an additional 42,250 shares during the last quarter. Institutional investors own 40.15% of the company’s stock.

LENSAR Trading Down 1.7 %

LNSR traded down $0.12 during midday trading on Friday, reaching $7.08. The company’s stock had a trading volume of 33,734 shares, compared to its average volume of 42,733. The stock’s 50-day moving average is $5.28 and its 200-day moving average is $4.75. LENSAR has a 1 year low of $2.10 and a 1 year high of $7.95. The firm has a market capitalization of $82.20 million, a price-to-earnings ratio of -4.85 and a beta of 0.59.

About LENSAR

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.